

patrys

INVESTOR PRESENTATION

November 2021



Safe harbour statement

The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of loss of capital invested and no return of income or payment of dividends. Neither Patrys nor any other entity or person in or associated with the Patrys group of companies guarantees any return (whether capital or income) or generally the performance of Patrys or the price at which its securities may trade.

In particular, this presentation is not a recommendation, offer or invitation to subscribe for or purchase Patrys securities. It is not for general distribution or third party reliance or use. While it has been prepared from sources Patrys believe to be reliable, Patrys cannot guarantee its accuracy or completeness and undertakes no obligation to advise of changes or updates to any such materials.

These materials are not exhaustive of all of the information a potential investor or their professional adviser would require. Nor do these materials take into account any specific objectives, financial situation or needs of investors. In addition, the past performance of Patrys cannot be assumed as indicative of the future performance of the company. For these and other reasons, before making any investment decision regarding Patrys securities you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk.

Where this presentation does contain any forward looking statements, those statements are only made as the date of the presentation and are to be considered “at-risk statements” not to be relied upon as they are subject to further research and to known and unknown risks, uncertainties and other factors that may lead to actual results differing from any forward looking statement. This is particularly the case with companies such as Patrys which operate in the field of researching, discovering, developing, and commercialising potential drugs intended for safe and effective for human treatments or therapies.

patrys

Overview

- Patrys is advancing its novel deoxymab antibody platform to develop a range of new therapeutic candidates that are:
  - Pan-cancer, independent of specific cell surface proteins
  - Able to penetrate and kill cancer cells
  - Able to deliver payloads intracellularly
  - Able to cross the blood-brain barrier (BBB)
- Deoxymabs have potential to be used as single agents, in combination, or as the basis for novel antibody drug conjugates, bispecific antibodies, and/or trafficking antibodies
- Deoxymabs target commercially attractive markets



Investment summary

Unique antibody platform

- Cancer targeting
- Cross blood brain barrier
- Block DNA repair

Attractive markets

- PARP inhibitors US$2.3B
- DNA repair deals
- ADC deals

Intellectual property

- Global rights
- All cancer indications
- Humanised antibodies

Multiple applications

- Single agent
- Combination agent
- Targeting agent

Utility for brain cancers

- Primary brain cancer
- Secondary brain cancer

Strong balance sheet

- A$9.8M cash (30 Sept)
- DX1 funded to the clinic
- Raising $7.8M[1] to advance DX3

1 $2.5M placement, $5.3M fully underwritten Rights Issue

Company snapshot

Shares	1.83B
Market cap	A$76M
Cash [1]	A$9.8M
Last qtr burn [1]	(A$1.2M)
Headquarters	Melbourne
Board	John Read (Chair) James Campbell (CEO & MD) Pamela Klein (NED) Suzy Jones (NED) Michael Stork (NED)
Substantial	Dr Dax Marcus Calder – 10.8% Mason Stevens – 6.3% Stork Holdings – 5.4%

Patrys (ASX: PAB) – 12-month price and volume

Price [2]	$0.042
12mth high - low	$0.063 - $0.017
Av. daily volume	11,931,109

[1] As at 30 September 2021
[2] As at close of trading, 27 October 2021

patrys

Board of Directors

John Read Chairman

- Experienced Chairman and Director in public, private and government organisations
- Extensive career in venture capital, private equity and commercialisation
- Chairman of CVC Limited (ASX: CVC), previously Eildon Capital Limited (ASX:EDC)

Dr James Campbell

- >20 years of international biotechnology research, management and leadership
- Previously the CFO and COO of ChemGenex Pharmaceuticals Limited (ASX:CXS) and of Evolve Biosystems Inc.
- Board member, Ausbiotech
- Board member, Prescient Therapeutics (ASX: PTX)

Dr Pamela M. Klein

- Former VP, Development at Genentech, led development of a large portfolio of drugs
- Former Chief Medical Officer of Intellikine (acquired by Millennium/Takeda)
- Board member at Argenx (Euronext & Nasdaq: ARGX)
- Chief Medical Officer of Olema Oncology (Nasdaq: OLMA)



Suzy Jones

- Founder and Managing Partner of DNA Ink, a life sciences advisory firm in San Francisco
- 20 years at Genentech in BD, product development and immunology research
- Board member at Calithera (Nasdaq: CALA)

Mike Stork

- Managing Director of Stork Holdings Ltd, active in Canadian technology start-up sector
- Director of multiple leading Canadian technology start-up companies

patrys



Technology Overview



First anticancer antibody therapeutic targeting DDR

- Deoxymabs are derived from an antibody, 3E10, which was isolated from a mouse model of the autoimmune disease lupus (SLE)
- Deoxymabs bind to DNA and have a unique combination of properties:
  - **Cancer seeking:** tumors release DNA which attracts deoxymabs
  - **Cell penetrating:** able to get into cells and the cell nucleus
  - **Block DNA damage repair (DDR):** killing dividing cancer cells
  - **Cross the blood-brain barrier (BBB):** to treat cancers in the brain
- Preclinical studies: deoxymabs safe with very little effect on normal, healthy cells
- Previous phase 1 clinical trial of 3E10 in 9 SLE patients showed no safety issues[1]



1 Spertini *et al.*, **J. Rheumatol**. 1999;26:2602–2608

Patrys' deoxymab platform

- Patrys' deoxymab platform is based on humanised versions of the mouse 3E10 antibodies
- Global rights to 3E10 antibodies for the treatment of cancer were acquired in 2016
- Patrys has created humanised versions of the 3E10 antibodies for therapeutic development:
  - **PAT-DX1**: two copies of a humanised binding domain of 3E10
  - **PAT-DX3**: a humanised version of the full IgG 3E10 mouse antibody
- PAT-DX1 and PAT-DX3 have different pharmaceutical properties, enabling their use for a wide range of healthcare applications
- Manufacturing and formulation program is underway <u>for both assets</u>



Deoxymab platform offers multiple therapeutic approaches

Single Agent



- Many cancers have pre-existing defects in their DNA damage repair (DDR) systems
- Additional blocking of DDR by deoxymabs can increase the amount of DNA damage to a level where it is lethal
- Consistently demonstrated ~50% increase in median survival in TNBC; pancreatic; brain cancers

Combination Therapies



- Radiation therapy and many chemo drugs work by causing damage to DNA
- Deoxymabs can slow the repair of the damage caused by these agents by blocking the DDR systems
- Combination with radiation demonstrated 3-fold better survival than radiation alone

Targeted Therapies



- Deoxymabs can direct delivery of payloads to cancer cells and the cell nucleus
- ADC opportunity (99.7% tumour growth inhibition)
- Imaging opportunity (collaboration with Imagion; ASX:IBX)
- Intracellular payload delivery

All of these approaches for using deoxymabs have been successfully demonstrated in preclinical studies



Deoxymab results



PAT-DX1 improves survival in glioblastoma

- Glioblastoma (GBM) is the most common form of primary brain cancer, with approximately 23,000 new cases diagnosed in the US each year
- GBM is highly aggressive with few effective treatment options (5-year survival rate = 5.6%)
- First line therapy for GBM is surgical removal of the tumour followed by radiation. Temozolomide (Temodar®) improves survival by 2 months
- ~ 40% of GBM tumors have a mutation in a protein call PTEN which is involved in the repair of DNA damage
- In GBM cells, single agent PAT-DX1:
  - has no impact on survival in cells with an intact PTEN protein
  - significantly decreases survival in cells with a PTEN mutation (DDR deficiency)
- In an animal model using human GBM explants, PAT-DX1 on its own was able to improve median survival by 47%

Mice with human GBM





deoxymab

patrys

PAT-DX1 improves survival with breast cancer metastases

- Approximately 230,000 women are diagnosed with breast cancer in the US each year
- 10%-15% have Triple Negative Breast Cancer (TNBC), an aggressive form with deficiencies in the BRCA1 gene (DNA damage repair)
- ~50% of TNBC patients develop brain metastases
- Like glioblastoma, TNBC brain metastases are very difficult to treat and patients usually have poor outcomes
- Mice with TNBC metastases treated with PAT-DX1 as a single agent (4 cycles), had 93% less brain metastases than control animals after 28 days
- This resulted in a 45% increase in median survival

TNBC [1] Brain Metastases Model





[1] TNBC = triple negative breast cancer which has DDR deficiency

deoxymab

patrys

PAT-DX1 improves survival in pancreatic cancer

- Pancreatic ductal adenocarcinoma (PDAC) is one of the most common and aggressive cancer types, with a 5-year survival rate of 2–9%[1]
- Globally, 460k new cases and 432k deaths in 2018
- Limited treatment options
- Projected to become the second leading cause of cancer death in the Western world by 2030
- First line therapy is surgical removal of the tumour followed by chemotherapy and radiation
- In an animal model of pancreatic cancer, single agent PAT-DX1 improved median survival by 47%



1. Arias-Pinilla & Modjtahedi. Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. *Cancers.* 2021

PAT-DX3 development path has been initiated

- Full sized, IgG deoxymab antibody, PAT-DX3, produced in September 2020
- PAT-DX3 shares biological activity with PAT-DX1, but is differentiated and complementary
  - Different pharmacokinetic profile
  - Can cross the blood brain barrier in animal models of brain cancer
  - Potential for use as a tumour targeting agent for antibody drug conjugates (more conjugation sites than PAT-DX1)
- Enabled by the financing in November/December 2021, Patrys has initiated a formal development program for PAT-DX3
- This will include the development of a manufacturing process to provide clinical grade PAT-DX3 at commercial scale, including establishing a stable, high-yielding producer cell line (stable cell line), and requisite manufacturing process optimization
- Responding to significant investment and deal activity in ADC technology, Patrys will conduct a range of ADC studies to explore the broad utility of DX3 in cancer and enhance potential partnering opportunities



Many solid tumors have DDR mutations



Cancer incidence rates (US cases p.a.)[1]

Brain	**25k**
Breast	**284k**
Pancreatic	**60k**
Colon	**150k**
Ovarian	**21k**



[1] American Cancer Society - Cancer Facts & Figures 2021 estimates

Principe et al 2020. Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort, Scientific Reports volume 10, Article number: 20223 (2020)

deoxymab

patrys

Combination therapies – improving glioblastoma treatments

- Radiation is a mainstay treatment for glioblastoma (GBM) patients and is used:
  - as a monotherapy (less frequently)
  - post-surgical removal of tumour tissue
  - in combination with the drug temozolomide (Temodar®)
- The efficacy of radiation therapy is dose-dependent, which is limited by potential side-effects:
  - risk of damage to adjacent healthy brain tissue
  - tiredness, weakness, loss of hair, nausea
  - worsening of brain cancer symptoms
- PAT-DX1 can improve the efficacy of low-dose radiation in a preclinical model of aggressive GBM
- PARP-inhibitors have had limited success in GBM due to their inability to cross the blood-brain barrier

Radiation + PAT-DX1 improves survival



Human glioblastoma cells implanted in mice. Seven mice were in each of four groups: 1. control, 2. radiation alone, 3. PAT-DX1 alone, 4. radiation + PAT-DX1. The bars represent improvement in survival over the control group at day 28.

PAT-DX3 ADC proof of principle

- Antibody drug conjugates are a fast-growing technology
- Use antibody to target delivery of toxic payload to cancer cells. Often superior benefits to antibodies alone
- Proof of principle study with PAT-DX3 conjugated to MMAE (payload used in approved ADCs)
- Clear tumour targeting effect when compared to control antibody
- 99.7% tumour growth inhibition after 3 weeks
- PAT-DX3-MMAE significantly increased survival compared to the control group of animals ($p<0.005$)

MCF7 Breast Cancer Model





deoxymab

patrys



Commercial landscape



Biologics typically transact earlier and at higher valuations than small molecules

Proportion of total deals[1]

Majority of biologic deals occur at the pre-clinical stage



Number of pre-clinical deals[1]

Significantly more interest in pre-clinical biologic assets



Pre-clinical avg. deal size[1,2]

Pre-clinical biologic deals executed at higher valuations



The value of Patrys' novel therapy is underpinned by potential for multiple applications to achieve better patient outcomes

Source: GlobalData

1. Small molecules and biologics transactions between 2017 and 2019
2. Deal size includes upfront and potential milestone payments

patrys

Recent deals for antibody and DNA Damage Repair drugs

Recent pre-clinical transactions (licensing, asset and corporate)[1]



Deal date	1Q19	1Q19	3Q19	1Q20	2Q20	2Q20	2Q20	3Q20	1Q20	1Q21	2Q21	2Q21
Deal type	Licensing	Licensing	Licensing	Licensing	Licensing	Alliance	Co-development	Strategic collaboration	Strategic collaboration	Strategic collaboration	Strategic collaboration	Licensing
Up front payment	US$56m	-	-	US$5m	US$65m	US$750m	US$120	US$1B	US$30m	US$40m	US$20m	US$200m
Licensee/ Acquirer	Jazz Pharmaceuticals	CTTQ	AMGEN	SeattleGenetics	Bristol-Myers Squibb	abbvie	gsk GlaxoSmithKline	AstraZeneca	MERCK	Lilly	NOVARTIS	Bristol-Myers Squibb
Licensor/ Target	CODIAK	abpro	Hummingbird Bioscience	FivePrime	REPARE THERAPEUTICS	Genmab	IDEAYA	Daiichi-Sankyo	artios DNA DAMAGE RESPONSE	Merus	artios DNA DAMAGE RESPONSE	agenus
Technology & target indication(s)	engEx™ Precision engineering platform for exosome therapeutics	DiversImmune ™ Platform: Novel bi-specific antibodies for cancer in China /Thailand territory	Antibody drug discovery platform for treatment of cancer	Novel antibody drug conjugate (ADC) platform for solid tumor cancers	SNIPRx®: Synthetic lethality discovery platform with potential in various cancers	Combination of Genmab's DuoBody® and AbbVie's payload and ADC technology	Synthetic lethality programs: MAT2A (solid tumors) and Werner Helicase (colorectal cancer)	Pre-clinical antibody drug conjugate, DS-1062, which targets TROP2 (NSCLC and breast cancer)	Pre-clinical discovery program for DDR small molecules	Biclonics® platform to develop three CD3-engaging T-cell re-directing bispecific antibody therapies	Pre-clinical discovery program for three DDR small molecules to combine with radiotherapies	Bi-specific program AGEN1777 that blocks TIGIT and a second undisclosed target

Source: Company information - all deal values exclude potential royalty payments

patrys



Looking ahead



Timeline


CY21
CY22
CY23
4Q
1Q
2Q
3Q
4Q
1Q
2Q
PAT-DX1
Production
Pre-clinical
Clinical
Engineering run
GMP production and formulation
GLP toxicology
Prepare & file Aust-HREA (IND)
Phase 1
PAT-DX3
Pre-production
Production
Pre-clinical
Cell line development
Stable cell line
Master Cell Bank
Upstream process development
Downstream process development
Engineering run
GLP toxicology
Additional development program funded by the Nov 2021 capital raise
Platform expansion
PAT-DX3 as single agent in animal models
PAT-DX3 based antibody drug conjugate (ADC) studies
Asset conjugation
Alternate deoxymab configurations and applications (eg bispecifics)
Deoxymab – diagnostic and nanoparticle collaborations

Anticipated newsflow / Milestones to end of 2022

	PAT-DX1 engineering production run completed	Q4 2021
*	PAT-DX3 stable cell line development completed	Q1 2022
	PAT-DX1 GLP toxicology studies completed	Q2 2022
*	PAT-DX3 final stable cell line selected	Q2 2022
	PAT-DX1 upstream process development completed	Q2 2022
	PAT-DX1 GMP production and formulation program completed	Q3 2022
	PAT-DX1 downstream process development completed	Q3 2022
	PAT-DX1 IND (as Australian Human Research Ethics Application) submitted	Q4 2022
	PAT-DX1 Phase 1 clinical study initiated	Q4 2022
*	PAT-DX3 master call bank completed	Q4 2022
*	PAT-DX3 engineering production run initiated	Q4 2022

Expansion of deoxymab platform (ADCs, bispecific antibodies, nanoparticles, imaging)	Ongoing
Scientific publications	Ongoing
New IP filings and patent grants	Ongoing
Alliances, collaborations and grants	Ongoing

* additional news flow arising from newly funded PAT-DX3 program

patrys

CONTACT

Dr. James Campbell

CEO and Managing Director

+61 3 9670 3273

info@patrys.com

www.patrys.com

Patrys Limited (ASX:PAB)